Cargando…

Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C

BACKGROUND: Cirrhotic cardiomyopathy is characterized by a set of cardiovascular modifications observed in advanced chronic liver disease. The aim of this study was to investigate cardiovascular alterations in chronic liver disease with different stages of fibrosis and to correlate cardiac involveme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marconi, Cecilia, Bellan, Mattia, Giarda, Paola, Minisini, Rosalba, Favretto, Serena, Burlone, Michela Emma, Franzosi, Lisa, Pirisi, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670288/ https://www.ncbi.nlm.nih.gov/pubmed/29118563 http://dx.doi.org/10.20524/aog.2017.0190

Ejemplares similares

Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents
por: Gualerzi, Alessandro, et al.
Publicado: (2018)

17,β‐estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle
por: Magri, Andrea, et al.
Publicado: (2016)

Liver Stiffness, Not Fat Liver Content, Predicts the Length of QTc Interval in Patients with Chronic Liver Disease
por: Bellan, Mattia, et al.
Publicado: (2019)

17β-Oestradiol Protects from Hepatitis C Virus Infection through Induction of Type I Interferon
por: Barbaglia, Matteo Nazzareno, et al.
Publicado: (2022)

Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients
por: De Benedittis, Carla, et al.
Publicado: (2020)

Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study
por: Vaghi, Gloria, et al.
Publicado: (2020)

Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease
por: Smirne, Carlo, et al.
Publicado: (2020)

Exposure to Plasma From Non-alcoholic Fatty Liver Disease Patients Affects Hepatocyte Viability, Generates Mitochondrial Dysfunction, and Modulates Pathways Involved in Fat Accumulation and Inflammation
por: Grossini, Elena, et al.
Publicado: (2021)

Red Cell Distribution Width and Platelet Count as Biomarkers of Pulmonary Arterial Hypertension in Patients with Connective Tissue Disorders
por: Bellan, Mattia, et al.
Publicado: (2019)

Role of Gas6 and TAM Receptors in the Identification of Cardiopulmonary Involvement in Systemic Sclerosis and Scleroderma Spectrum Disorders
por: Bellan, Mattia, et al.
Publicado: (2020)

Pancreatobiliary Reflux Resulting in Pancreatic Ascites and Choleperitoneum after Gallbladder Perforation
por: Rapetti, Rachele, et al.
Publicado: (2008)

Role of Osteopontin as a Potential Biomarker of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Other Connective Tissue Diseases (CTDs)
por: Bellan, Mattia, et al.
Publicado: (2021)

Increased Levels of ICOS and ICOSL Are Associated to Pulmonary Arterial Hypertension in Patients Affected by Connective Tissue Diseases
por: Bellan, Mattia, et al.
Publicado: (2022)

COVID-19 Biomarkers at the Crossroad between Patient Stratification and Targeted Therapy: The Role of Validated and Proposed Parameters
por: Rizzi, Manuela, et al.
Publicado: (2023)

Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms
por: Bellan, Mattia, et al.
Publicado: (2019)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Identification of a Functional, CRM-1-Dependent Nuclear Export Signal in Hepatitis C Virus Core Protein
por: Cerutti, Andrea, et al.
Publicado: (2011)

Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review
por: Bellan, Mattia, et al.
Publicado: (2018)

Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis
por: Smirne, Carlo, et al.
Publicado: (2019)

Clinical Relevance of Liver Involvement in the Clinical Course of Systemic Sclerosis
por: Lorena, Maria, et al.
Publicado: (2022)

The Gas6/TAM System and Multiple Sclerosis
por: Bellan, Mattia, et al.
Publicado: (2016)

Comment on “Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis”
por: Bellan, Mattia, et al.
Publicado: (2019)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Levosimendan Inhibits Peroxidation in Hepatocytes by Modulating Apoptosis/Autophagy Interplay
por: Grossini, Elena, et al.
Publicado: (2015)

Adrenal Dysfunction in Portal Hypertensive Rats with Acute Hemorrhage
por: Lee, Fa-Yauh, et al.
Publicado: (2014)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
por: Manfredi, Giulia Francesca, et al.
Publicado: (2023)

SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study
por: Mangia, Alessandra, et al.
Publicado: (2019)

Plasma Pattern of Extracellular Vesicles Isolated from Hepatitis C Virus Patients and Their Effects on Human Vascular Endothelial Cells
por: Grossini, Elena, et al.
Publicado: (2023)

Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
por: Smirne, Carlo, et al.
Publicado: (2021)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Portal Hypertension in Alcohol-Associated Hepatitis
por: McConnell, Matthew J., et al.
Publicado: (2023)

Portal Hypertension
por: Sun, Mingyu, et al.
Publicado: (2018)

Portale Hypertension
por: Bauer, J., et al.
Publicado: (2011)

Prognostic Markers in Hospitalized COVID-19 Patients: The Role of IP-10 and C-Reactive Protein
por: Rizzi, Manuela, et al.
Publicado: (2022)

Pulmonary Arterial Hypertension Associated with Portal Hypertension and HIV Infection: Comparative Characteristics and Prognostic Predictors
por: Dardi, Fabio, et al.
Publicado: (2023)

Hematological Indices in Portal Hypertension: Cirrhosis versus Noncirrhotic Portal Hypertension
por: Sahin, Abdurrahman, et al.
Publicado: (2018)

Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis
por: Cho, Eun Ju, et al.
Publicado: (2015)

Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension
por: Cunningham, Morven E., et al.
Publicado: (2019)

Transient elastography and von Willebrand factor as predictors of portal hypertension and decompensation in children
por: Goel, Akshat, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7gnou4442hdk8h4pv5fuq5m8hc